AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca’s OPTIMISE-CKD study, officially titled ‘A Multinational, Observational, Retrospective, Secondary Data Study Describing Management and Treatment in Routine Clinical Practice Among Patients With Chronic Kidney Disease,’ aims to assess the management and treatment of chronic kidney disease (CKD) in Spain. This study is significant as it evaluates the incidence of renal disease and the use of kidney-protective treatments, providing insights into current clinical practices.
The study tests two interventions: pre-pricing and reimbursement, and post-pricing and reimbursement cohorts. These interventions focus on patients with newly diagnosed renal disease, assessing their renal function and treatment outcomes over specified periods.
The study is observational with a cohort model and a retrospective time perspective. It does not involve any allocation or masking, focusing on understanding real-world treatment patterns and outcomes for CKD patients.
The study began on December 4, 2024, with a primary completion date yet to be announced. The latest update was submitted on July 14, 2025. These dates are crucial as they mark the progress and current status of the study, indicating ongoing data collection and analysis.
The outcomes of this study could influence AstraZeneca’s stock performance by providing data that may support the efficacy of their treatments, potentially boosting investor confidence. In the competitive landscape of CKD treatments, such insights are valuable for maintaining a competitive edge.
The OPTIMISE-CKD study is currently recruiting, with further details available on the ClinicalTrials portal.